AccelaPure is a drug discovery company. Using its technology called Supercritical Fluid Chromatography, the Company has developed AccelaPure Purification Platform. The platform is used for purification partnerships with the pharmaceutical industry and through the development of its own nature product-based drug compounds.

Accium BioSciences offers highly sensitive bioanalytical services with a focus on early-stage drug development. Its facility is built around a state-of-the-art accelerator mass spectrometer that is used to obtain pharmacokinetics, bioavailability and metabolite profiling of new drug candidates. 

Acucela is a biotechnology company discovering new drug therapies for eye diseases. Neurodegenerative retinal diseases such as macular degeneration, Stargardt's disease, retinitis pigmentosa and glaucoma. Acucela uses proprietary disease-specific assays and technologies to identify and develop compounds that have safety and efficacy in treating different retinal eye diseases. These technologies represent a tremendous leap forward over existing eye disease models.

AerovectRx is an early stage company developing novel pulmonary drug delivery technology licensed from the U.S. Centers for Disease Control and Prevention (CDC). As a platform technology, it is designed to deliver a wide variety of therapies and vaccines through mass immunization and personal patient use. Its near-term strategy is to commercialize the CDC platform technology into multiple device and single-patient-use products.

Alder Biotherapeutics is a biopharmaceutical company that uses its proprietary technologies to identify, develop, produce and market its own antibody therapeutics. This focus has resulted in two proprietary platform technologies that accelerate antibody discovery and development, allowing the Company to play a role in addressing unmet medical needs. It has developed two unique antibody technologies that together increase antibody potency, drastically accelerate production cycles, and lower overall production costs.

Algos Therapeutics is a pain-focused drug discovery company with a vision of developing breakthrough prescription drugs to treat painful chronic conditions such as diabetic neuropathy, post-herpetic neuralgia, lower back pain, osteoarthritis pain, intractable cancer pain, and pain associated with gastrointestinal disorders. Its technology is centered on behavioral models that mimic chronic pain states in humans and serve as powerful tools for evaluating drug candidates.

Angiogen is a biopharmaceutical discovery company developing novel therapies for treating cancerous solid, vascular tumors. Angiogen’s first therapy is based upon combining two classes of FDA approved drugs into one anti-angiogenesis cancer-fighting treatment.

ApoImmune manufactures of recombinant proteins for the treatment of cancer, diabetes and infectious diseases. The Company is founded on a platform technology that is used for immunomodulation. This technology platform, referred to as ProtEx, was shown to be highly effective in preventing the development of cancer in animals and eradicated cancer in a significant majority of animals with metastasized, rapidly growing tumors.

Applied Genetic Technology uses viral vectors for gene therapy. Its strategy is to identify diseases that can be treated by delivery of a known gene and for which no other adequate treatments are available. Applied Genetic Technology lead product candidate is a treatment for Alpha One Antitrypsin Deficiency (Alpha One) an inherited cause of Emphysema. Alpha One is the most common potentially fatal hereditary disease of Western World adults.

Argos Therapeutics is acting in the immunotherapy area. By using technology, therapeutic methods and expertise in dendritic cell biology, Argos is developing therapies in the areas of oncology, infectious diseases, autoimmune disorders and transplantation. Its focus is bringing to market therapeutic options that offer new promise for treatment of intractable diseases, an improved safety profile and better patient quality of life during treatment.

Arteriocyte's mission is the development of cellular therapies to treat ischemic disease with an initial focus on coronary applications. The therapeutic objective is "therapeutic angiogenesis" or the generation of new blood vessels to replace or supplement those blood vessels which no longer adequately supply a tissue. These cellular therapies will eventually help patients suffering from a number of ichemic conditions including coronary artery disease and peripheral vascular disease.